Updates

SciTech Development, LLC, a clinical stage specialty pharmaceutical company focused on novel, advanced drug delivery mechanisms for use with cancer therapeutics, is pleased to announced that it has received IRB Approval to enter the clinic at Rush University Medical Center (RUMC) for ST-001 nanoF...

Read More
Learn more

View Dr. Brian Leyland-Jones (SciTech Development's Chief Medical Officer) Keynote Speaker's Presentation from the 2020 MedInvest Virtual Infectious Diseases and Immunology Conference June 15, 2020 titled "Cancer and COVID-19 Pneumonia and Pneumonitis" https://youtu.be/Zwn13AT-Ufg

Learn more

"Cortland graduate seeks virus treatment approval", May 8, 2020 Cortland Standard. David Schaffer, a consultant for biomedical companies and Cortland native, is a strategic adviser to SciTech Development LLC, a Michigan-based biomedical company. SciTech produces a drug called nanoFenretinide, whi...

Read More
Learn more

COVID-19 Therapeutic Opportunity: ST-001 nanoFenretinide may offer additional support in the battle against the COVID-19 pandemic. For investment and partnering opportunities contact Lou Scarmoutzos | (617) 283-2182 | lou@scitechdevelopment.com or Earle Holsapple | (313) 263-4887 | eth@scitechdev...

Read More
Learn more

Lead drug ST-001 nanoFenretinide

SciTech Development, LLC, is a clinical stage specialty pharmaceutical company focused on novel, advanced drug delivery mechanisms for use with cancer therapeutics. SciTech’s patented and differentiated drug delivery system, SDV, is a proprietary intravenous, phospholipid-based, nanoparticle product. SDV enables drug assets, such as fenretinide, that are water insoluble, to be distributed through the circulatory system in sufficient quantities and doses to reach the target cells and produce a therapeutic effect while maintaining low toxicity levels. Fenretinide, the first asset that SciTech is combining with SDV, is the active pharmaceutical ingredient (API) in SciTech's lead drug ST-001 nanoFenretinide.

The U.S. FDA has recently accepted SciTech’s Investigational New Drug Application (IND) for ST-001 nanoFenretinide treatment of T-cell non-Hodgkin's lymphoma (NHL). Additionally, the FDA has granted Orphan Drug Designation status for ST-001 in the treatment of two types of NHL: peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). Solid preclinical and clinical data makes the case for the use of fenretinide in the treatment of additional blood disorders and solid tumors such as small cell lung, breast, pancreatic, neuroblastoma and other cancers.

SciTech has recently submitted a proposal to the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Health and Human Services (HHS) for the use of its lead drug product ST-001 nanoFenretinide in the treatment of patients infected with COVID-19 (SARS-CoV-2). Fenretinide has demonstrated in-vitro antiviral activity against a number of viruses including MERS, Dengue, Zika, West Nile, HIV, and HCV.

For ST-001 nanoFenretinide investment and partnering opportunities contact Earle Holsapple | +1-313-938-5517 | eth@scitechdevelopment.com  

Contact Us

Contact

Call now
  • (313) 938-5517

Address

Get directions
281 Kercheval Avenue
Grosse Pointe Farms, MI 48236
United States

Business Hours

Mon:7:00 AM – 9:00 PM
Tue:7:00 AM – 9:00 PM
Wed:7:00 AM – 9:00 PM
Thu:7:00 AM – 9:00 PM
Fri:7:00 AM – 9:00 PM
Sat:7:00 AM – 9:00 PM
Sun:7:00 AM – 9:00 PM
Contact Us
Message sent. We'll get back to you soon.